GSK269962A

GSK269962A Basic information
Product Name:GSK269962A
Synonyms:GSK 269962;N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide;GSK269962A(GSK269962);N-(3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl)oxy)phenyl)-4-(2-morpholinoethoxy)benzamide;CS-1126;N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide;ROCK inhibitor GS269962A;GSK 269962A;GSK-269962A;GSK269962;GSK 269962;GSK-269962
CAS:850664-21-0
MF:C29H30N8O5
MW:570.6
EINECS:
Product Categories:
Mol File:850664-21-0.mol
GSK269962A Structure
GSK269962A Chemical Properties
Melting point 125 - 127°C
density 1.45
storage temp. under inert gas (nitrogen or Argon) at 2–8 °C
solubility DMSO (Slightly), Methanol (Slightly)
form Solid
pka13.19±0.70(Predicted)
color Off-White
Safety Information
MSDS Information
GSK269962A Usage And Synthesis
DescriptionTwo Rho-associated kinases (ROCKS), ROCK1 and ROCK2, act downstream of the G protein Rho to regulate cytoskeletal stability. The ROCKs play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal. GSK269962 is a selective ROCK inhibitor with IC50 values of 1.6 and 6 nM for ROCK1 and ROCK2, respectively. It displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. GSK269962 has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). Oral administration of 1-30 mg/kg GSK269962 can dose-dependently lower blood pressure in spontaneously hypertensive rats.
UsesGSK 269962 is a potent and selective Rho kinase (ROCK) inhibitor.
storageStore at +4°C
GSK269962A Preparation Products And Raw materials

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.